Ruth R Hagen1,2, Jet van den Dijssel1,2, Lisan H Kuijper3, Christine Kreher3, Thomas Ashhurst4,5, S Marieke van Ham3,6, Anja Ten Brinke3, Carolien E van de Sandt1,7, Niels J M Verstegen3, Laura Y L Kummer8, Maurice Steenhuis3, Mariel Duurland3, Rivka de Jongh3, Nina de Jong3, C Ellen van der Schoot2, Amélie V Bos3, Erik Mul9, Katherine Kedzierska7,10, Koos P J van Dam8, Eileen W Stalman8, Laura Boekel11, Gertjan Wolbink3,11, Sander W Tas12, Joep Killestein13, Zoé L E van Kempen13, Luuk Wieske8,14, Taco W Kuijpers15, Filip Eftimov8, Theo Rispens3. 1. Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, University of Amsterdam, Amsterdam, Netherlands. 2. Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands. 3. Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, University of Amsterdam, Amsterdam, Netherlands. 4. Sydney Cytometry Core Research Facility, Charles Perkins Centre, Centenary Institute, and The University of Sydney, Sydney, Australia. 5. School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. 6. Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, Netherlands. 7. Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia. 8. Department of Neurology and Neurophysiology, Amsterdam Neuroscience, University of Amsterdam, Amsterdam, Netherlands. 9. Department of Research Facilities, Sanquin Research, Amsterdam, Netherlands. 10. Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Japan. 11. Department of Rheumatology, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands. 12. Amsterdam Rheumatology and immunology Center, Department of Rheumatology and Clinical Immunology, University of Amsterdam, Amsterdam, Netherlands. 13. Amsterdam UMC, Vrije Universiteit, Department of Neurology, Amsterdam, Netherlands. 14. Department of Clinical Neurophysiology, St Antonius Hospital, Nieuwegein, Netherlands. 15. Department of Pediatric Immunology, Rheumatology and Infectious Disease, University of Amsterdam, Amsterdam, Netherlands.
Abstract
Background: Patients affected by different types of autoimmune diseases, including common conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated with immunosuppressants to suppress disease activity. It is not fully understood how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral and cellular immunity induced by infection and/or upon vaccination is affected by immunosuppressants. Methods: The dynamics of cellular immune reactivation upon vaccination of SARS-CoV-2 experienced MS patients treated with the humanized anti-CD20 monoclonal antibody ocrelizumab (OCR) and RA patients treated with methotrexate (MTX) monotherapy were analyzed at great depth via high-dimensional flow cytometry of whole blood samples upon vaccination with the SARS-CoV-2 mRNA-1273 (Moderna) vaccine. Longitudinal B and T cell immune responses were compared to SARS-CoV-2 experienced healthy controls (HCs) before and 7 days after the first and second vaccination. Results: OCR-treated MS patients exhibit a preserved recall response of CD8+ T central memory cells following first vaccination compared to HCs and a similar CD4+ circulating T follicular helper 1 and T helper 1 dynamics, whereas humoral and B cell responses were strongly impaired resulting in absence of SARS-CoV-2-specific humoral immunity. MTX treatment significantly delayed antibody levels and B reactivation following the first vaccination, including sustained inhibition of overall reactivation marker dynamics of the responding CD4+ and CD8+ T cells. Conclusions: Together, these findings indicate that SARS-CoV-2 experienced MS-OCR patients may still benefit from vaccination by inducing a broad CD8+ T cell response which has been associated with milder disease outcome. The delayed vaccine-induced IgG kinetics in RA-MTX patients indicate an increased risk after the first vaccination, which might require additional shielding or alternative strategies such as treatment interruptions in vulnerable patients. Funding: This research project was supported by ZonMw (The Netherlands Organization for Health Research and Development, #10430072010007), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (#792532 and #860003), the European Commission (SUPPORT-E, #101015756) and by PPOC (#20_21 L2506), the NHMRC Leadership Investigator Grant (#1173871).
Background: Patients affected by different types of autoimmune diseases, including common conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated with immunosuppressants to suppress disease activity. It is not fully understood how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific humoral and cellular immunity induced by infection and/or upon vaccination is affected by immunosuppressants. Methods: The dynamics of cellular immune reactivation upon vaccination of SARS-CoV-2 experienced MS patients treated with the humanized anti-CD20 monoclonal antibody ocrelizumab (OCR) and RA patients treated with methotrexate (MTX) monotherapy were analyzed at great depth via high-dimensional flow cytometry of whole blood samples upon vaccination with the SARS-CoV-2 mRNA-1273 (Moderna) vaccine. Longitudinal B and T cell immune responses were compared to SARS-CoV-2 experienced healthy controls (HCs) before and 7 days after the first and second vaccination. Results: OCR-treated MS patients exhibit a preserved recall response of CD8+ T central memory cells following first vaccination compared to HCs and a similar CD4+ circulating T follicular helper 1 and T helper 1 dynamics, whereas humoral and B cell responses were strongly impaired resulting in absence of SARS-CoV-2-specific humoral immunity. MTX treatment significantly delayed antibody levels and B reactivation following the first vaccination, including sustained inhibition of overall reactivation marker dynamics of the responding CD4+ and CD8+ T cells. Conclusions: Together, these findings indicate that SARS-CoV-2 experienced MS-OCR patients may still benefit from vaccination by inducing a broad CD8+ T cell response which has been associated with milder disease outcome. The delayed vaccine-induced IgG kinetics in RA-MTX patients indicate an increased risk after the first vaccination, which might require additional shielding or alternative strategies such as treatment interruptions in vulnerable patients. Funding: This research project was supported by ZonMw (The Netherlands Organization for Health Research and Development, #10430072010007), the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (#792532 and #860003), the European Commission (SUPPORT-E, #101015756) and by PPOC (#20_21 L2506), the NHMRC Leadership Investigator Grant (#1173871).
Authors: Louise C Rowntree; Thi H O Nguyen; Lukasz Kedzierski; Melanie R Neeland; Jan Petersen; Jeremy Chase Crawford; Lilith F Allen; E Bridie Clemens; Brendon Chua; Hayley A McQuilten; Anastasia A Minervina; Mikhail V Pogorelyy; Priyanka Chaurasia; Hyon-Xhi Tan; Adam K Wheatley; Xiaoxiao Jia; Fatima Amanat; Florian Krammer; E Kaitlynn Allen; Sabrina Sonda; Katie L Flanagan; Jaycee Jumarang; Pia S Pannaraj; Paul V Licciardi; Stephen J Kent; Katherine A Bond; Deborah A Williamson; Jamie Rossjohn; Paul G Thomas; Shidan Tosif; Nigel W Crawford; Carolien E van de Sandt; Katherine Kedzierska Journal: Immunity Date: 2022-06-08 Impact factor: 43.474
Authors: Jerry S Wolinsky; Douglas L Arnold; Bruno Brochet; Hans-Peter Hartung; Xavier Montalban; Robert T Naismith; Marianna Manfrini; James Overell; Harold Koendgen; Annette Sauter; Iain Bennett; Stanislas Hubeaux; Ludwig Kappos; Stephen L Hauser Journal: Lancet Neurol Date: 2020-10-29 Impact factor: 44.182
Authors: Eric Y Wang; Tianyang Mao; Jon Klein; Yile Dai; John D Huck; Jillian R Jaycox; Feimei Liu; Ting Zhou; Benjamin Israelow; Patrick Wong; Andreas Coppi; Carolina Lucas; Julio Silva; Ji Eun Oh; Eric Song; Emily S Perotti; Neil S Zheng; Suzanne Fischer; Melissa Campbell; John B Fournier; Anne L Wyllie; Chantal B F Vogels; Isabel M Ott; Chaney C Kalinich; Mary E Petrone; Anne E Watkins; Charles Dela Cruz; Shelli F Farhadian; Wade L Schulz; Shuangge Ma; Nathan D Grubaugh; Albert I Ko; Akiko Iwasaki; Aaron M Ring Journal: Nature Date: 2021-05-19 Impact factor: 49.962
Authors: Thi H O Nguyen; Marios Koutsakos; Carolien E van de Sandt; Jeremy Chase Crawford; Liyen Loh; Sneha Sant; Ludivine Grzelak; Emma K Allen; Tim Brahm; E Bridie Clemens; Maria Auladell; Luca Hensen; Zhongfang Wang; Simone Nüssing; Xiaoxiao Jia; Patrick Günther; Adam K Wheatley; Stephen J Kent; Malet Aban; Yi-Mo Deng; Karen L Laurie; Aeron C Hurt; Stephanie Gras; Jamie Rossjohn; Jane Crowe; Jianqing Xu; David Jackson; Lorena E Brown; Nicole La Gruta; Weisan Chen; Peter C Doherty; Stephen J Turner; Tom C Kotsimbos; Paul G Thomas; Allen C Cheng; Katherine Kedzierska Journal: Nat Commun Date: 2021-05-11 Impact factor: 14.919
Authors: Niels J M Verstegen; Victor Ubels; Hans V Westerhoff; S Marieke van Ham; Matteo Barberis Journal: Front Immunol Date: 2021-09-20 Impact factor: 7.561
Authors: Rebecca H Haberman; Seungha Um; Jordan E Axelrad; Rebecca B Blank; Zakwan Uddin; Sydney Catron; Andrea L Neimann; Mark J Mulligan; Ramin Sedaghat Herat; Simon J Hong; Shannon Chang; Arnold Myrtaj; Ghoncheh Ghiasian; Peter M Izmirly; Amit Saxena; Gary Solomon; Natalie Azar; Jonathan Samuels; Brian D Golden; Paula Rackoff; Samrachana Adhikari; David P Hudesman; Jose U Scher Journal: Lancet Rheumatol Date: 2022-04-01
Authors: Dami A Collier; Isabella A T M Ferreira; Prasanti Kotagiri; Rawlings P Datir; Eleanor Y Lim; Emma Touizer; Bo Meng; Adam Abdullahi; Anne Elmer; Nathalie Kingston; Barbara Graves; Emma Le Gresley; Daniela Caputo; Laura Bergamaschi; Kenneth G C Smith; John R Bradley; Lourdes Ceron-Gutierrez; Paulina Cortes-Acevedo; Gabriela Barcenas-Morales; Michelle A Linterman; Laura E McCoy; Chris Davis; Emma Thomson; Paul A Lyons; Eoin McKinney; Rainer Doffinger; Mark Wills; Ravindra K Gupta Journal: Nature Date: 2021-06-30 Impact factor: 49.962
Authors: Jeffrey A Sparks; Zachary S Wallace; Andrea M Seet; Milena A Gianfrancesco; Zara Izadi; Kimme L Hyrich; Anja Strangfeld; Laure Gossec; Loreto Carmona; Elsa F Mateus; Saskia Lawson-Tovey; Laura Trupin; Stephanie Rush; Patricia Katz; Gabriela Schmajuk; Lindsay Jacobsohn; Leanna Wise; Emily L Gilbert; Ali Duarte-García; Maria O Valenzuela-Almada; Guillermo J Pons-Estel; Carolina A Isnardi; Guillermo A Berbotto; Tiffany Y-T Hsu; Kristin M D'Silva; Naomi J Patel; Lianne Kearsley-Fleet; Martin Schäfer; Sandra Lúcia Euzébio Ribeiro; Samar Al Emadi; Liselotte Tidblad; Carlo Alberto Scirè; Bernd Raffeiner; Thierry Thomas; René-Marc Flipo; Jérôme Avouac; Raphaèle Seror; Miguel Bernardes; Maria Margarida Cunha; Rebecca Hasseli; Hendrik Schulze-Koops; Ulf Müller-Ladner; Christof Specker; Viviane Angelina de Souza; Licia Maria Henrique da Mota; Ana Paula Monteiro Gomides; Philippe Dieudé; Elena Nikiphorou; Vanessa L Kronzer; Namrata Singh; Manuel F Ugarte-Gil; Beth Wallace; Akpabio Akpabio; Ranjeny Thomas; Suleman Bhana; Wendy Costello; Rebecca Grainger; Jonathan S Hausmann; Jean W Liew; Emily Sirotich; Paul Sufka; Philip C Robinson; Pedro M Machado; Jinoos Yazdany Journal: Ann Rheum Dis Date: 2021-05-28 Impact factor: 19.103